Theralizumab - TheraMAB LLC
Alternative Names: TAB-08; TABO8Latest Information Update: 12 Oct 2021
At a glance
- Originator TheraMAB
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Systemic lupus erythematosus
- Phase I/II Plaque psoriasis
- No development reported Chronic lymphocytic leukaemia; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 06 Oct 2021 Theramab completes a phase I trial in Solid tumours (Metastatic disease, Inoperabe/Unresectable, Late-stage disease) in Russia (NCT03006029).
- 28 Mar 2020 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Russia (IV, Infusion)
- 21 May 2018 Theramab LLC terminates a phase II trial in Systemic lupus erythematosus in Russia due to administrative reasons (IV) (NCT02711813)